Search clinical trials for: surufatinib fulvestrant chidamide

Total 710 results

Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Hutchison Medipharma Limited

Completed

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Tumors

United States, Italy
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers (CRC-C1721)

Relative Bioavailability

China
Hutchison Medipharma Limited

Active, not recruiting

Open-label Study of Surufatinib in Japanese Patients

Neuroendocrine Tumors | Non-hematologic Malignancy

Japan
The First Affiliated Hospital of Zhengzhou University

Recruiting

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

Breast Cancer | Breast Cancer Female

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Biliary Tract Cancer

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

Healthy

China
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
Hutchmed
BeiGene

Active, not recruiting

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors | Metastatic Solid Tumor | Anaplastic Thyroid Cancer

United States
Hutchison Medipharma Limited

Unknown

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Biliary Tract Cancer

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Breast Cancer
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Hormone Receptor-positive Advanced Breast Cancer
Fudan University

Not yet recruiting

Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

Hormone Receptor-positive Advanced Breast Cancer
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Biliary Tract Cancer

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaborators

Not yet recruiting

Surufatinib in G3 Neuroendocrine Tumors

Neuroendocrine Tumor Grade 3
Qilu Hospital of Shandong University

Not yet recruiting

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

Biliary Tract Carcinoma
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Healthy

United States
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
Huiqiang Huang

Unknown

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Lymphoma, Extranodal NK-T-Cell | EBV
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Head and Neck Cancers - Salivary Gland

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Experimental
Changhai Hospital

Not yet recruiting

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor

China
Fudan University

Not yet recruiting

A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma Adult
Fudan University

Recruiting

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

China
Hutchmed

No longer available

Expanded Access Program of Surufatinib

Neuroendocrine Tumors

United States
Sun Yat-sen University

Recruiting

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Sarcoma

China
Hutchison Medipharma Limited

Completed

Surufatinib Renal Impairment Study

Renal Impairment

United States
Sun Yat-sen University

Recruiting

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Triple Negative Breast Cancer

China
Sun Yat-sen University

Unknown

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Experimental Tumor

China
Hutchison Medipharma Limited

Completed

Surufatinib Hepatic Impairment Study

Hepatic Impairment

United States
Shanghai Changzheng Hospital

Not yet recruiting

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Advanced Solid Tumors With Neuroendocrine Differentiation
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
Zhejiang University

Recruiting

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

T Lymphoblastic Leukemia/Lymphoma

China
Sichuan University

Recruiting

Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Leukemia, Myeloid, Acute

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

China
Liling Zhang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Newly Diagnosed Peripheral T-cell Lymphoma

China
Peking University
Peking University International Hospital; Hebei Medical University Fourth Hospital

Unknown

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Experimental Tumor

China
Dong mei

Unknown

Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Adenocystic Carcinoma

China
Fujian Cancer Hospital

Recruiting

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Advanced Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Advanced or Metastatic Solid Tumors

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

PTCL

China
Ruijin Hospital

Unknown

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

China
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China

3

Subscribe